NCT01226316: Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
- State
- Completed
- Phase
- Phase 1
- People
- 285 taking part
- Started
- 1 Dec 2010
- Primary completion
- 26 Apr 2019
- Arms
- Part A and B Schedule 1, Continuous dosing, Parts A,B,C,D Schedule 2, Intermittent dosing, Parts A and B Schedule 3, Intermittent dosing., Parts E and F, Intermittent dosing with Fulvestrant
- Results
- None posted
- 22 Oct 2010: Trial registered
- 1 Dec 2010: Trial started
- 3 Dec 2024: Trial completed